127317-03-7
基本信息
垂体后叶粉
神经垂体素
垂体腺苷酸环化酶激活肽-27
人,羊,大鼠PACAP (1-27)肽
M-PACAP
PACAP-27
PACAP 1-27
PACAP-27 (human
PACAP (1-27) AMIDE
Human PACAP-(1-27)
PACAP 27 AMIDE, OVINE
powdered posterior pitultary
PACAP-27 (HUMAN, OVINE, RAT)
物理化学性质
外观性状 | 本品是猪、牛、羊等动物的脑垂体后叶经脱水、干燥、研细制成。含有缩宫素(催产素,oxytocin,约20单位)和少量的升压素(vasopressin,0.5单位),二者结构极相似,都是含有二硫键的九肽。粉剂是淡黄色或淡灰色无晶形粉末,有特臭,在水中几乎不溶。 有兴奋子宫、促进乳汁排出作用,缩宫素剂量大时可使血管扩张,但升压素剂量大时可收缩血管,还有利尿作用。 |
密度 | 1.45±0.1 g/cm3(Predicted) |
储存条件 | −20°C |
储存条件 | −20°C |
溶解度 | H2OPeptide Solubility and Storage Guidelines:1.??Calculate the length of the peptide.2.??Calculate the overall charge of the entire peptide according to the following table:3.??Recommended solution: |
形态 | solid |
颜色 | white |
水溶解性 | Soluble to 1 mg/ml in water |
InChIKey | RZGBUJXSKLDAFE-XVTUQGJWNA-N |
制备方法
丙酮、乙醚处理是为了除去低分子物质和脂类,保证澄明度。
猪神经垂体[P2O5]→粗后叶粉[丙酮、乙醚]→[25℃, 4h]垂体后叶粉
垂体后叶粉的精制 将垂体后叶粉加入0.25%的乙酸分别提取两次,第1次加入5倍量,第2次加入2倍量,各于50℃搅拌提取15min,过滤。两次提取完毕,合并滤液,将滤液迅速加热至100℃,保持15min,趁热加入0.5%三氯叔丁醇(体积比为1:1,必要时加活性炭处理),速冷至30℃以下,冷藏过夜后,反复过滤至澄清。乙酸浸出液含无效蛋白质与自解酶,加热可使其凝固和破坏(注意:缩宫素的催产效价在碱性或强酸下易失效。在弱酸如pH3-4时稳定,且100℃流通蒸气灭菌30min或热压灭菌亦稳定)。
垂体后叶粉[0.25%乙酸]→[50℃, 15min]滤液[0.5%三氯叔丁醇]→[冷藏, 过滤]精制后叶粉液
后叶粉注射液制剂的制备 测定后叶粉液的效价后,加注射用水使其达到10.5 U/ml,并加适量三氯叔丁醇达到0.5%,用冰醋酸调pH为3.5,用垂熔漏斗过滤,灌封,100℃流通蒸气灭菌半小时,即得垂体后叶注射液成品。
后叶粉液[测效价]→[pH3.5]后叶注射液[过滤,灭菌]→后叶注射液成品。
安全数据
WGK Germany | 3 |
WGK Germany | 3 |
应用领域
常见问题列表
神经垂体素可用于血液透析慢性低血压患者中的应用及护理;治疗肺结核咯血;治疗食管静脉曲张破裂出血等。
IC50: 3 nM (rat PAC1), 2 nM (rat VPAC1), 5 nM (human VPAC2)
Radioligand receptor binding assays with I-monoiodinated PACAP (1-27), human, ovine, rat confirms the presence of PAC -receptors on AR4-2J cells, since PACAP (1-27), human, ovine, rat and PACAP(1–38) equipotently displaces radioligand binding with a K d of 1-2 nM, whereas vasoactive intestinal peptide (VIP) is 1000-fold less potent. PACAP (1-27), human, ovine, rat exhibits a distinct and much higher susceptibility to VIP-amino acid substitutions. PACAP (1-27), human, ovine, rat has potency and binding affinity to stimulate IP3 and cAMP formation in AR4-2J cells.
The inhibitory effect of pituitary adenylate cyclase activating polypeptide (PACAP (1-27), human, ovine, rat) on the increase in total pulmonary resistance (RL) causes either by allergen or histamine in anaesthetized, ventilated guinea-pigs is studied. PACAP (1-27), human, ovine, rat given via i.v. infusion (0.045-4.5 nmol/kg/min) dose-dependently reduces the increase in RL caused by inhaled ovalbumin and histamine. At the highest dose, PACAP (1-27), human, ovine, rat prevented the increase in RL caused by ovalbumin and histamine completely. Infusion of PACAP (1-27), human, ovine, rat and the β2-adrenoceptor agonist, salbutamol (0.045-4.5 nmol/kg/min) inhibit the increase in RL similarly, but salbutamol increases the heart rate more than PACAP (1-27), human, ovine, rat.
神经垂体素价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-P0176 | 神经垂体素 PACAP (1-27), human, ovine, rat | 127317-03-7 | 500 μg | 800元 |
2025/02/08 | HY-P0176 | 神经垂体素 PACAP (1-27), human, ovine, rat | 127317-03-7 | 1 mg | 1250元 |
2025/02/08 | HY-P0176 | 神经垂体素 PACAP (1-27), human, ovine, rat | 127317-03-7 | 5 mg | 4000元 |